No connection

Search Results

MENS vs MGNX

MENS
Jyong Biotech Ltd.
BEARISH
Price
$2.79
Market Cap
$212.1M
Sector
Healthcare
AI Confidence
95%
MGNX
MacroGenics, Inc.
BEARISH
Price
$3.47
Market Cap
$220.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
MENS
--
MGNX
--
Forward P/E
MENS
--
MGNX
-3.58
P/B Ratio
MENS
-8.91
MGNX
3.95
P/S Ratio
MENS
--
MGNX
1.48
EV/EBITDA
MENS
-121.13
MGNX
-1.03

Profitability

Gross Margin
MENS
0.0%
MGNX
-22.53%
Operating Margin
MENS
0.0%
MGNX
-29.34%
Profit Margin
MENS
0.0%
MGNX
-49.91%
ROE
MENS
--
MGNX
-86.94%
ROA
MENS
-5.44%
MGNX
-17.56%

Growth

Revenue Growth
MENS
--
MGNX
113.0%
Earnings Growth
MENS
--
MGNX
--

Financial Health

Debt/Equity
MENS
--
MGNX
0.66
Current Ratio
MENS
0.62
MGNX
5.1
Quick Ratio
MENS
0.62
MGNX
4.71

Dividends

Dividend Yield
MENS
--
MGNX
--
Payout Ratio
MENS
0.0%
MGNX
0.0%

AI Verdict

MENS BEARISH

MENS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical lack of fundamental value. The company reports a negative Price-to-Book ratio of -8.91, indicating negative shareholders' equity, and a Current Ratio of 0.62, signaling an immediate liquidity crisis. With zero reported revenue and a catastrophic 95% price decline over the last six months, the stock appears to be in a speculative death spiral. Recent short-term gains are likely volatility-driven 'dead cat bounces' rather than a fundamental recovery.

Strengths
Recent short-term price recovery (+40.9% in 1 month)
Small market cap allows for high volatility spikes
Operates in the high-growth Healthcare/Biotech sector
Risks
Negative book value indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.62)
Complete absence of revenue and profit margins
MGNX BEARISH

MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.

Strengths
Exceptional YoY revenue growth of 113%
Strong short-term liquidity with a Current Ratio of 5.10
Manageable Debt/Equity ratio of 0.66
Risks
Critical fundamental health (Piotroski F-Score 0/9)
Negative gross margins (-22.53%) indicating an unsustainable cost structure
Severe earnings volatility and frequent misses (Average surprise -286.67%)

Compare Another Pair

MENS vs MGNX: Head-to-Head Comparison

This page compares Jyong Biotech Ltd. (MENS) and MacroGenics, Inc. (MGNX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile